Merck Posts Record Q2 Sales, Raises Guidance Amid KEYTRUDA Momentum

Merck & Co., a leading pharmaceutical company, reported a significant increase in second-quarter sales, reaching $16.6 billion, up 5% from the same period last year.

The company's KEYTRUDA family of products, which includes intravenous KEYTRUDA and subcutaneous KEYTRUDA QLEX, generated $8.4 billion in revenue, a 4% increase year-over-year.

Merck also announced that it has raised its full-year 2026 revenue guidance to $66.3-$67.3 billion, representing 2-4% growth.